Traduction de «reimbursement for » (Néerlandais → Français) :

Two social categories were defined with this variable, the BIM u (increased reimbursement, mostly corresponding to people with a low income level) and BO (normal reimbursement).
Two social categories were defined with this

presented to the Delphi panel. A consensus appeared from the first round that citizens should be involved for strategic decisions (setting budgetary priority) and patients for more operational decisions (e.g. product reimbursement decision linked to a specific disease).
that citizens should be involved for strategic decisions (setting budgetary priority) and patients for more operational decisions (e.g. product reimbursement decision linked to a specific disease).

The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but (Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”. Only 26% would choose to inform the patient outside the existing organs, and with a stronger preference on informing after the decision is taken.
The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but ( Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”.

Diagnosis-Related Groups; Health Care Reform, Cost Allocation; Reimbursement Mechanisms
Cost Allocation; Diagnosis-Related Groups; Health Care Reform; Reimbursement Mechanisms

Cost of bupropion was not included as this was not reimbursed by the HMO in the context of this intervention.
Cost of Buproprion was not included as this was not reimbursed by the HMO in the context of this intervention.

BIM: Bénéficiaire à Intervention Majorée (beneficiary of increased reimbursement); BO: Bénéficiaire Ordinaire
variable, the BIM u (increased reimbursement, mostly corresponding to people with a low income level) and BO (normal reimbursement). Measurement of inequalities

Average Wholesale Price litigation Claims have been brought against various pharmaceutical companies, including Novartis subsidiaries, alleging that they have fraudulently overstated the Average Wholesale Price and “best price”, which are, or have been, used by the US federal and state governments in the calculation of, respectively, Medicare reimbursements and Medicaid rebates.
Litige concernant le prix de gros moyen Des plaintes ont été déposées contre différentes sociétés pharmaceutiques, dont des filiales de Novartis, prétendant que celles-ci ont frauduleusement exagéré le prix de gros moyen (average wholesale price [AWP]) et le «meilleur prix» qui sont ou ont été utilisés par le gouvernement américain et des gouvernements d’Etat pour calculer les remboursements des médicaments dans le cadre du programme Medicare et les rabais dans celui de Medicaid.

National representation A number of FAMHP employees represent the Minister of Public Health on a number of commissions and consultation platforms, such as the commission for the reimbursement of medicines (CTG - CRM) and the technical pharmaceutical board (TFR - CTP) of the RIZIV - INAMI, the price commission for pharmaceutical proprietary products of the FPS Economy, and of the FANC.
National representation A number of FAMHP employees represent the Minister of Public Health on a number of commissions and consultation platforms, such as the commission for the reimbursement of medicines (CTG - CRM) and the technical pharmaceutical board (TFR - CTP) of the RIZIV - INAMI, the price commission for pharmaceutical proprietary products of the FPS Economy, and of the FANC.

The data in this source need, of course, to agree with those that have been approved or determined by the competent authority for marketing authorisation – MA (FAMHP), price (FPS Economy) and reimbursement modalities (RIZIV-INAMI), respectively.
The data in this source need, of course, to agree with those that have been approved or determined by the competent authority for marketing authorisation – MA (FAMHP), price (FPS Economy) and reimbursement modalities (RIZIV-INAMI), respectively.

mechanisms, individual private insurances reimburse several healthcare Macro-level data on the needs should be complemented with dataa that services.
transparency in ambulatory supplements as well as in private hospital illustrated that in Belgian hospitals nurses have, on average, to take care insurances (the percentage of people with private hospital insurance, and for more patients compared to other EU countries.